Clincal/Molculr RiskDirected Therapy for New Dxd Medulloblastoma

A Clinical And Molecular Risk-Directed Therapy For Newly Diagnosed Medulloblastoma

November 22, 2017

  • Clinical Trial Information

    Trial Contact: El-Shami, Jessica; Francois, Laetitia Claire; Leffin, Melissa; Spinelli, Jennifer

  • IRB No: 13.198.12

    Protocol Abbrev: SJMB12

    Principal Investigator: Amy A Smith, MD

    Sub Investigators: Eslin, Don MD; Giusti, Vincent MD; Sutphin, Robert MD; Levy, Alejandro MD; AguilarBonilla, Ana MD; Pope, Michele ARNP; Sullivan Darden, Kelly ARNP

    Phase: Drug: Phase II

    Age Group: Pediatric

    Secondary Protocol No: SJMB12

    Treatment: Chemotherapy

    Applicable Disease Sites: Brain

    Therapies Involved: Radiation: Craniospinal Irradiation Other: Aerobic Training Other: Neurocognitive Remediation Drug: Chemotherapy (multiple) ID: NCT01878617

  • Objective

    To find out if participants with low-risk WNT tumors can be treated with a lower dose of radiation to the brain and spine, and a lower dose of the chemotherapy drug cyclophosphamide while still achieving the same survival rate as past St. Jude studies with fewer side effects. To find out if adding targeted chemotherapy after standard chemotherapy will benefit participants with SHH positive tumors. To find out if adding new chemotherapy agents to the standard chemotherapy will improve the outcome for intermediate and high risk Non-WNT Non-SHH tumors. To define the cure rate for standard risk Non-WNT Non-SHH tumors treated with reduced dose cyclophosphamide and compare this to participants from the past St. Jude study.

  • Key Eligibility

    Ages Eligible for Study: 3 Years to 21 Years; Genders Eligible for Study: Both; Accepts Healthy Volunteers: No